Storm Therapeutics has closed a $56 million series C financing as the British biotech kicks off a phase 2 sarcoma trial of ...

The Pfizer-backed Series C round will see Storm work out an accelerated approval pathway for STC-15 in sarcoma.

FDA orphan drug designation provides incentives including regulatory support, tax credits, fee exemptions, and seven years of ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms ...

Bowers has released his award-winning sports documentary, Pedro Cueto: Power of a Dream, now streaming globally on Amazon Fire TV, the Apple iPad, and anywhere the Free Movies+ app is available (via ...

STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...

STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...

A new clinical trial led by the Penn State College of Medicine-based Beat Childhood Cancer Research Consortium will evaluate ...

People who survived cancer as teens and young adults are at increased risk of developing cancer later in their lives, ...

Background: Survivors of cancer in adolescence and young adulthood are at increased risk for subsequent primary neoplasms, but studies using Canadian data are limited. We sought to quantify the risk ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, ...

Country and blues singer Nat Myers provided his fans with an update on his battle against cancer this week. Myers has been ...